Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 4, 1999, Pages 295-302

  Bressolle, Françoise ^a   Joulia, Jean M ^a,b   Pinguet, Frédéric ^b   Ychou, Marc ^b   Astre, Cécile ^b   Duffour, Jacqueline ^b   Gomeni, Roberto ^a,c  

^a UNIV MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

^c ASTRAZENECA   (United Kingdom)

Author keywords

5 Fluorouracil; Circadian rhythm; Colorectal cancer; Population pharmacokinetics

Indexed keywords

CREATININE; FLUOROURACIL; FOLINIC ACID; LIVER ENZYME;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BAYES THEOREM; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CIRCADIAN RHYTHM; COLORECTAL CANCER; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTINUOUS INFUSION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTOPENIA; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BAYES THEOREM; BODY FLUID COMPARTMENTS; CIRCADIAN RHYTHM; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PREDICTIVE VALUE OF TESTS;

EID: 0032798073     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050980     Document Type: Article

References (39)

1. Al-Banna MK, Kelman AW, Whiting B (1990) Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 18: 347
2. Beal SL, Sheiner LB (1992) NONMEM User's Guide. University of California at San Francisco, San Francisco
3. de Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, Grange JD, Gonzalez-Canali G, Demuynck B, Louvet C, Seroka J, Dray C, Debray J (1988) High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer 24: 1499
4. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, Bedenne L (1995) A prospective randomized trial comparing 5FU bolus with low dose folinic acid (FUFOL1d) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proceedings of ASCO 14: A455
5. Door RT, Fritz WL (1980) Cancer chemotherapy handbook, Elsevier, Amsterdam, p 435
6. Endrenyi L (1981) Design of experiments for estimating enzyme and pharmacokinetic experiments. In: Endrenyi L (ed) Kinetic data analysis, design and analysis of enzyme and pharmacokinetic experiments. Plenum Press, New York, pp 137
7. Erlichman C, Fine S, Elhakim T (1986) Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep 70: 903
8. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG (1996) Relationship between 5-fluorouracil (5- FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441
9. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J (1998) Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and Leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 16: 1470
10. Goldberg JA, Kerr DJ, Willmont N, McKllop JH, McArdle CS (1988) Pharmacokinetics and pharmacodynamics of locoregional 5-fluorouracil in advanced colorectal liver metastases. Br J Cancer 57: 186
11. Gomeni R (1998) Visual-NM user's manual. R.D.P.P., Montpellier, France
12. Harris BE, Song RL, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for a circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197
13. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203
14. Johnson PWM, Thompson PI, Seymour MT, Deasy NP, Thuraisingham RC, Slevin ML, Wrigley PFM (1991) A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 64: 603
15. Joulia JM, Pinguet F, Grosse PY, Astre C, Bressolle F (1997) Pharmacokinetics of 5-fluorouracil (5-FU) in patients with colorectal cancer receiving 5-FU bolus plus continuous infusion with high dose folinic acid (LV5FU2). Anticancer Res 17: 2727
16. Joulia JM, Pinguet F, Grosse PY, Astre C, Bressolle F (1997) Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography. Application to a pharmacokinetic study. J Chromatogr B 692: 427
17. Lokich J, ed (1987) Cancer chemotherapy by infusion. Precept Press, Chicago
18. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion of fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7: 425
19. Mentré F, Gomeni R (1995) A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat 5: 141
20. Metzger G, Massari C, Etienne MC, Comisso M, Brienza S, Touitou Y, Milano G, Bastian G, Misset JL, Levi F (1994) Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther 56: 190
21. Milano G, Roman P, Khater R, Frenay M, Renee N, Namer M (1988) Dose versus pharmacokinetics for predicting tolerance for 5-day continuous infusion of 5-FU. Int J Cancer 41: 537
22. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10: 1171
23. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M (1988) Circadian rhythm-varying plasma concentration of 5- fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48: 1676
24. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW, Valone F, Labianca R, Doroshow JH, Pretrelli N (1992) Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by Leucovorin in patients with advanced colorectal cancer evidence in terms of response rate. J Clin Oncol 10: 896
25. Pinedo HM, Peters GJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653
26. Poon M, O'Connell M, Moertel GG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Maillard JA, Laurie JA, Tschetter LK (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407
27. Santini J, Milano G, Thyss A, Renee N, Viens P, Schneider M, Demard F (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287
28. Schalhorn A, Kühl M (1992) Clinical pharmacokinetics of fluorouracil and folinic acid. Semin Oncol 19: 82
29. Seifert P, Baker LH, Reed LM, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection treatment of patients with colorectal adenocarcinoma. Cancer 36: 123
30. Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML (1994) Lack of effect of interferon α2a upon fluorouracil pharmacokinetics. Br J Cancer 70: 727
31. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503
32. Sheiner LB, Beal SL (1981) Evaluation of methods for estimating population pharmacokinetic parameters II biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 9: 635
33. Sheiner LB, Rosenberg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drugs dosage. Comput Biomed Res 5: 411
34. Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16: 64
35. Trump D, Egorin MJ, Forrest A, Willson JKV, Remick S, Tutsch K (1991) Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9: 2027
36. Tuchman M, Roemeling RV, Hrushesky WA, Sothern RB, O'Dea RF (1989) Dihydropyrimidine reductase activity in human blood mononuclear cells. Enzyme 42: 15
37. Van Groeningen CJ, Pinedo HM, Heddes J, Kok R, de Jong PJM, Wattel E, Peters GJ, Lankelma J (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 48: 6956
38. Wattanatorn W, McLeod HL, Macklon F, Reid M, Kendle KE, Cassidy J (1997) Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer. Pharmacotherapy 17: 881
39. Yoshida T, Araki E, Iigo M, Fujii T, Yoshino M, Shimada Y, Saito D, Tajiri H, Yamaguchi H, Yoshida S, Yoshimo M, Ohkura H, Yoshimori M, Okazaki N (1990) Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol 26: 352